World Health Organization Raises Alert Over Critical Scarcity of Obesity Injections

Fewer than a tenth of patients who could benefit from weight-loss injections like Wegovy are able to get them, states the global health agency as it publishes its initial advice on the therapies.

With in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for increased and just access to GLP-1 medication.

Per estimates, over two billion will be living with obesity by 2030 without intervention.

"Our latest guidance acknowledges that obesity is a lifelong illness that can be treated with holistic and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.

High costs, limited production capacity, and distribution challenges are significant barriers to broad availability to the treatments that can aid individuals in losing substantial weight, notes the organization.

Skinny Jab Scarcity

Even in the current most optimistic scenario, the production of these medications might only reach about 100 million people – fewer than 10% of those who need them, according to the health organization.

The advice encourages nations and manufacturers to expand availability, through measures including licensing agreements.

Exclusive production rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in several nations in 2026.

How Weight-Loss Jabs Operate

These medications imitate a natural hormone to slow digestion, curb appetite and increase satiety so people consume fewer calories.

People commonly see weight reduction in the initial weeks of beginning the weekly injections.

Research points to people may see weight return a year later of stopping the drug, because their normal appetite return.

Being carrying excess weight elevates your likelihood for developing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and certain cancers.

Excess weight affects people in every country and was responsible for over three and a half million deaths worldwide in 2024, according to the WHO.

Carolyn Spence
Carolyn Spence

A seasoned gambling analyst with over a decade of experience in the UK market, focusing on player behavior and regulatory changes.